Ratings Amarin Corporation plc

Equities

AMRN

US0231112063

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.865 ^USD	+2.94%		+2.06%	-0.57%

May. 28	European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	MT
May. 28	Amarin Says Greece Approves Vazkepa for National Reimbursement; Signs Commercialization Agreement With Vianex	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company is in a robust financial situation considering its net cash and margin position.
The company's share price in relation to its net book value makes it look relatively cheap.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AMARIN CORPORATION PLC	-0.57%	355M	C
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B	B+
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B	B+
BIONTECH SE	-4.68%	24.28B	B+
ARGENX SE	-0.82%	21.96B	B
GENMAB A/S	-10.12%	18.16B	A-
WUXI APPTEC CO., LTD.	-42.12%	16.37B	A-
BEIGENE, LTD.	-17.47%	15.56B	B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B	C+
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes